



Immune Checkpoint Inhibitor Therapy

Guest Editor:

Dr. Eduardo Castañón Álvarez

Department of Oncology, Clínica
Universidad de Navarra, 31008
Pamplona, Spain

Deadline for manuscript
submissions:

closed (31 August 2021)

Message from the Guest Editor

Dear Colleagues,

Immunotherapy has provoked a paradigm shift in the treatment of cancer. Since 2013, we have known that immunotherapy is the cornerstone for the treatment of tumors such as melanoma, non-small cell lung carcinoma, head and neck carcinoma, and bladder carcinoma. Different immune checkpoints such as PD(L)1 or CTLA-4 inhibitors have become the first agents to have FDA and EMA approval for treating different carcinomas. Despite all the efforts, there are still some patients who are primarily resistant or who become resistant after being on treatment. T cell exhaustion, T regs upregulation, or MDSC activity have been proposed as mechanisms of resistance among others to immunotherapy agents. To overcome this lack of response to immunotherapy agents, different approaches such as combinations with chemotherapy, radiotherapy, or targeted therapy are under investigation. At this point, it is not only tumor mutations that are relevant to choose the proper treatment, but a deeper knowledge of the host immune system is also required.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química e Bioquímica (CQB), Faculdade de Ciências, Universidade de Lisboa (FCUL), Rua Ernesto de Vasconcelos, Campo Grande, Edifício C8, 5º Piso, 1749-016 Lisboa, Portugal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPus / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q2 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Pharmaceutical Science*)

Contact Us

Pharmaceuticals Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceuticals
pharmaceuticals@mdpi.com